EP1005470B1
(en)
|
1997-08-22 |
2007-08-01 |
AstraZeneca AB |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
ATE482946T1
(en)
|
1999-02-10 |
2010-10-15 |
Astrazeneca Ab |
QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATE PRODUCTS THEREFOR
|
US7083791B2
(en)
|
1999-03-25 |
2006-08-01 |
Genesis Research & Development Corporation Limited |
Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
|
US20030143676A1
(en)
*
|
1999-03-25 |
2003-07-31 |
Genesis Research And Development Corporation Limited |
Fibroblast growth factor receptors and methods for their use
|
GB9918057D0
(en)
*
|
1999-07-30 |
1999-10-06 |
Univ Bristol |
Therapeutic agents
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
SE9904177D0
(en)
*
|
1999-11-18 |
1999-11-18 |
Astra Ab |
Novel compounds
|
CA2395520A1
(en)
|
1999-12-21 |
2001-06-28 |
Sugen, Inc. |
4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
|
EP1110957A1
(en)
|
1999-12-24 |
2001-06-27 |
Applied Research Systems ARS Holding N.V. |
Benzazole derivatives and their use as JNK modulators
|
US6323029B1
(en)
|
2000-01-19 |
2001-11-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of glycogen synthase kinase 3 beta expression
|
US6316259B1
(en)
|
2000-01-21 |
2001-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of glycogen synthase kinase 3 alpha expression
|
AU2001236720A1
(en)
*
|
2000-02-05 |
2001-08-14 |
Bemis, Guy |
Compositions useful as inhibitors of erk
|
FR2804959B1
(en)
*
|
2000-02-15 |
2006-04-28 |
Centre Nat Rech Scient |
USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
|
JP2003525296A
(en)
*
|
2000-02-28 |
2003-08-26 |
スージェン・インコーポレーテッド |
3- (pyrrolyllactone) -2-indolinone compounds as kinase inhibitors
|
EP1313726A1
(en)
|
2000-08-09 |
2003-05-28 |
AstraZeneca AB |
Quinoline derivatives having vegf inhibiting activity
|
CA2415022A1
(en)
|
2000-08-09 |
2002-02-14 |
Astrazeneca Ab |
Cinnoline compounds
|
EP1347972A1
(en)
*
|
2000-12-19 |
2003-10-01 |
Smithkline Beecham Plc |
Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
|
DE60122939T2
(en)
|
2000-12-21 |
2007-01-11 |
Nitromed, Inc., Bedford |
SUBSTITUTED ARYL COMPOUNDS AS NEW, CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS, AND USE PROCESSES
|
SE0101230L
(en)
*
|
2001-04-06 |
2002-10-07 |
Innoventus Project Ab |
New use of a tyrosine kinase inhibitor
|
GB0108770D0
(en)
|
2001-04-06 |
2001-05-30 |
Eisai London Res Lab Ltd |
Inhibitors
|
AU2002259071A1
(en)
*
|
2001-04-30 |
2002-11-11 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
|
ATE330608T1
(en)
*
|
2001-06-29 |
2006-07-15 |
Ab Science |
THE USE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
|
DE60227709D1
(en)
*
|
2001-06-29 |
2008-08-28 |
Ab Science |
THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
JP2005500041A
(en)
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
Potent, selective and non-toxic C-KIT inhibitor
|
JP2004530730A
(en)
*
|
2001-06-29 |
2004-10-07 |
アブ サイエンス |
Use of a potent, selective and non-toxic c-kit inhibitor for treating tumor angiogenesis
|
DK1401413T3
(en)
*
|
2001-06-29 |
2007-03-26 |
Ab Science |
Use of tyrosine kinase inhibitors for the treatment of allergic diseases
|
WO2003004007A2
(en)
|
2001-06-29 |
2003-01-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
|
ES2275021T3
(en)
*
|
2001-09-27 |
2007-06-01 |
Smithkline Beecham Corporation |
DERIVATIVES OF AZOXOINDOL AS INHIBITORS OF TRK PROTEIN KINASE FOR THE TREATMENT OF CANCER AND CHRONIC PAIN.
|
NZ534171A
(en)
|
2002-02-01 |
2007-06-29 |
Astrazeneca Ab |
Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
|
US7534800B2
(en)
|
2002-03-28 |
2009-05-19 |
Eisai R & D Development Co., Ltd. |
7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
|
IL164082A0
(en)
|
2002-03-28 |
2005-12-18 |
Eisai Co Ltd |
Azaindole derivatives and pharmaceutical compositions containing the same
|
EP1501511A4
(en)
*
|
2002-05-06 |
2006-06-07 |
Univ Washington |
Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
|
GB0305142D0
(en)
|
2003-03-06 |
2003-04-09 |
Eisai London Res Lab Ltd |
Synthesis
|
EP1599475A2
(en)
|
2003-03-06 |
2005-11-30 |
Eisai Co., Ltd. |
Jnk inhibitors
|
EP1628975A2
(en)
|
2003-05-16 |
2006-03-01 |
Eisai Co., Ltd. |
Jnk inhibitors
|
AR045037A1
(en)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0402137D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
KR101216372B1
(en)
*
|
2004-03-30 |
2013-01-04 |
버텍스 파마슈티칼스 인코포레이티드 |
Azaindoles useful as inhibitors of JAK and other protein kinases
|
NZ550448A
(en)
*
|
2004-05-14 |
2010-11-26 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
WO2005113561A1
(en)
*
|
2004-05-20 |
2005-12-01 |
Sugen, Inc. |
Cyclicsulfonate pyrrole indolinones as kinase inhibitors
|
GB0423554D0
(en)
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
JP2009503001A
(en)
*
|
2005-08-01 |
2009-01-29 |
エフ.ホフマン−ラ ロシュ アーゲー |
Heterocyclic benzylamino derivatives, their production and use as pharmaceuticals
|
GB0516156D0
(en)
|
2005-08-05 |
2005-09-14 |
Eisai London Res Lab Ltd |
JNK inhibitors
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
JP2009512711A
(en)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Regulation of neurogenesis by PDE inhibition
|
JP5324785B2
(en)
|
2005-10-28 |
2013-10-23 |
武田薬品工業株式会社 |
Heterocyclic amide compounds and uses thereof
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007084557A2
(en)
|
2006-01-17 |
2007-07-26 |
Vertex Pharmaceuticals Incorporated |
Azaindoles useful as inhibitors of janus kinases
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
AU2007245495A1
(en)
|
2006-04-26 |
2007-11-08 |
Astex Therapeutics Limited |
Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
NZ577798A
(en)
|
2006-12-21 |
2012-04-27 |
Vertex Pharma |
5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
BRPI0821227A2
(en)
|
2007-12-19 |
2015-06-16 |
Cancer Rec Tech Ltd |
Compound, pharmaceutical composition, method for preparing same, use of a compound, method for treating a disease or disorder, for inhibiting raf function and for inhibiting cell proliferation, inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more more of them
|
GB0807609D0
(en)
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
EP2379561B1
(en)
|
2008-11-25 |
2015-11-04 |
University Of Rochester |
Mlk inhibitors and methods of use
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
DK2442809T3
(en)
|
2009-06-17 |
2016-12-19 |
Vertex Pharma |
Inhibitors of the replication of influenza virus
|
PL2531502T3
(en)
|
2010-02-01 |
2014-08-29 |
Cancer Research Tech Ltd |
1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
|
CN103153994B
(en)
|
2010-05-24 |
2016-02-10 |
罗切斯特大学 |
Bicyclic heteroaryl kinase inhibitor and using method
|
KR20140014110A
(en)
|
2010-12-16 |
2014-02-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Inhibitors of influenza viruses replication
|
CN102115469A
(en)
*
|
2011-03-21 |
2011-07-06 |
浙江大学 |
Preparation method for indoline-2-one derivative and application of same
|
US9493452B2
(en)
*
|
2011-03-24 |
2016-11-15 |
Southern Methodist University |
Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
|
US8669363B2
(en)
|
2011-03-24 |
2014-03-11 |
Southern Methodist University |
Quinoxaline compounds and derivatives
|
CN103702998A
(en)
|
2011-07-05 |
2014-04-02 |
沃泰克斯药物股份有限公司 |
Processes and intermediates for producing azaindoles
|
UA118010C2
(en)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
INFLUENCES OF INFLUENZA VIRUS REPLICATION
|
PT2807160T
(en)
*
|
2012-01-26 |
2019-10-28 |
Angion Biomedica Corp |
Antifibrotic compounds and uses thereof
|
WO2013142831A1
(en)
|
2012-03-23 |
2013-09-26 |
Southern Methodist University |
Methods of making and using thioxothiazolidine and rhodanine derivatives as hiv-1 and jsp-1 inhibitors
|
CN104884059B
(en)
|
2012-11-30 |
2018-08-10 |
罗切斯特大学 |
Mixing pedigree kinase inhibitor for HIV/AIDS treatments
|
CN108276278B
(en)
|
2013-11-13 |
2021-04-20 |
沃泰克斯药物股份有限公司 |
Method for preparing influenza virus replication inhibitor
|
PT3068776T
(en)
|
2013-11-13 |
2019-08-26 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
GB201320732D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Methods of chemical synthesis
|
CN104447733B
(en)
*
|
2015-01-05 |
2016-08-17 |
中国药科大学 |
1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application
|
CN104876928B
(en)
*
|
2015-05-07 |
2016-09-14 |
浙江司太立制药股份有限公司 |
7-azaindole quinoline-2-ketone compounds and preparation method thereof
|
MA42422A
(en)
|
2015-05-13 |
2018-05-23 |
Vertex Pharma |
INHIBITORS OF INFLUENZA VIRUS REPLICATION
|
JP6704416B2
(en)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Methods for preparing inhibitors of influenza virus replication
|
JP6661766B2
(en)
*
|
2015-11-12 |
2020-03-11 |
エルジー・ケム・リミテッド |
Pharmaceutical composition containing a 7-azaindoline-2-one derivative or a pharmaceutically acceptable salt thereof as an active ingredient
|
PT3466934T
(en)
|
2016-05-31 |
2024-04-30 |
Taiho Pharmaceutical Co Ltd |
Sulfonamide compound or salt thereof
|
US10889555B2
(en)
|
2016-05-31 |
2021-01-12 |
Taiho Pharmaceutical Co., Ltd. |
Sulfonamide compound or salt thereof
|
CN106432228A
(en)
*
|
2016-09-06 |
2017-02-22 |
浙江司太立制药股份有限公司 |
4-oximido-1-piperidyl fragment containing 7-azaindolin-2-one compound and preparation method therefor
|
CN106397436A
(en)
*
|
2016-09-06 |
2017-02-15 |
浙江司太立制药股份有限公司 |
5-bromo-7-azaindoline-2-one compounds and preparation method thereof
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
WO2019071144A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
Use of p38 inhibitors to reduce expression of dux4
|